TriSalus Life Sciences Inc. (TLSI)
NASDAQ (NMS) NASDAQ (NMS) Primary 
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
TriSalus Life Sciences NASDAQ: TLSI outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity's Global Growth Conference, with management emphasizing the company's pressure-enabled delivery technology for solid-tumor treatments.
TriSalus Life Sciences Q2 Earnings Call Highlights
TriSalus Life Sciences NASDAQ: TLSI reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, representing projected growth of 19% to 26% over 2025.
TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript
TriSalus Life Sciences Q1 Earnings Call Highlights
TriSalus Life Sciences NASDAQ: TLSI reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.33 per share a year ago.
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know
TriSalus Life Sciences, Inc. (TLSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript
TriSalus Life Sciences, Inc. (TLSI) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization Transcript
TriSalus Life Sciences, Inc. ( TLSI ) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization November 12, 2025 10:00 AM EST Company Participants Mary Szela - CEO, President & Director Richard Marshall Andrea Marasso Conference Call Participants Nicole Lamparello Francis Kang Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good morning, and welcome to the TriSalus Life Sciences KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the TriSalus website following the conclusion of the event.
TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 AM ET Company Participants David B. Patience - Chief Financial Officer Jeremy Feffer - Corporate Participant Mary T.
TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.21 per share a year ago.
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.54 per share a year ago.
